Switch theme
Sign up to access all valuation multiples
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
1992
94.3K+
LTM Revenue $43.2B
LTM EBITDA $14.7B
$242B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AstraZeneca has a last 12-month revenue of $43.2B and a last 12-month EBITDA of $14.7B.
In the most recent fiscal year, AstraZeneca achieved revenue of $72.6B and an EBITDA of $20.7B.
AstraZeneca expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AstraZeneca valuation multiples based on analyst estimates| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | $43.2B | XXX | XXX | XXX | XXX |
| Gross Profit | $35.5B | XXX | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | XXX | XXX | XXX |
| EBITDA | $14.7B | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBIT | $13.7B | XXX | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | XXX | XXX | XXX |
| Net Profit | $10.3B | XXX | XXX | XXX | XXX |
| Net Margin | 24% | XXX | XXX | XXX | XXX |
| Net Debt | $31.1B | XXX | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AstraZeneca's stock price is GBP 104 (or $139).
AstraZeneca has current market cap of GBP 161B (or $216B), and EV of GBP 180B (or $242B).
See AstraZeneca trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $242B | $216B | XXX | XXX | XXX | XXX | $8.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AstraZeneca has market cap of $216B and EV of $242B.
AstraZeneca's trades at 4.2x EV/LTM Revenue multiple, and 12.2x EV/LTM EBITDA.
Equity research analysts estimate AstraZeneca's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AstraZeneca has a P/E ratio of 15.6x.
See valuation multiples for AstraZeneca and 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Market cap (current) | $216B | XXX | XXX | XXX | XXX |
| EV (current) | $242B | XXX | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | XXX | XXX | XXX |
| EV/EBITDA | 12.2x | XXX | XXX | XXX | XXX |
| EV/EBIT | 13.2x | XXX | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | XXX | XXX | XXX |
| P/E | 15.6x | XXX | XXX | XXX | XXX |
| EV/FCF | 32.1x | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAstraZeneca's last 12 month revenue growth is 1%
AstraZeneca's revenue per employee for the last 12 months averaged $0.8M, while opex per employee averaged $0.5M for the same period.
AstraZeneca's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AstraZeneca's rule of X is 38% (another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AstraZeneca and other 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | XXX | XXX | XXX |
| Bessemer Rule of X | 38% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 62% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AstraZeneca acquired XXX companies to date.
Last acquisition by AstraZeneca was XXXXXXXX, XXXXX XXXXX XXXXXX . AstraZeneca acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AstraZeneca founded? | AstraZeneca was founded in 1992. |
| Where is AstraZeneca headquartered? | AstraZeneca is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does AstraZeneca have? | As of today, AstraZeneca has 94.3K+ employees. |
| Who is the CEO of AstraZeneca? | AstraZeneca's CEO is Mr. Pascal Soriot. |
| Is AstraZeneca publicy listed? | Yes, AstraZeneca is a public company listed on LON. |
| What is the stock symbol of AstraZeneca? | AstraZeneca trades under AZN ticker. |
| When did AstraZeneca go public? | AstraZeneca went public in 1993. |
| Who are competitors of AstraZeneca? | Similar companies to AstraZeneca include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AstraZeneca? | AstraZeneca's current market cap is $216B |
| What is the current revenue of AstraZeneca? | AstraZeneca's last 12 months revenue is $43.2B. |
| What is the current revenue growth of AstraZeneca? | AstraZeneca revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of AstraZeneca? | Current revenue multiple of AstraZeneca is 4.2x. |
| Is AstraZeneca profitable? | Yes, AstraZeneca is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AstraZeneca? | AstraZeneca's last 12 months EBITDA is $14.7B. |
| What is AstraZeneca's EBITDA margin? | AstraZeneca's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of AstraZeneca? | Current EBITDA multiple of AstraZeneca is 12.2x. |
| What is the current FCF of AstraZeneca? | AstraZeneca's last 12 months FCF is $5.6B. |
| What is AstraZeneca's FCF margin? | AstraZeneca's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of AstraZeneca? | Current FCF multiple of AstraZeneca is 32.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
